La Jolla Pharmaceutical Company and Vanderbilt University Enter Exclusive Research and License Agreement Covering Novel BMP Type-I Receptor Inhibitors

Collaboration seeks to develop new therapies for bone, other diseases

Grant enhances mental illness drug research efforts